1. Agency, U.S., 2016. for Healthcare Research and Quality (AHRQ). Decisional dilemmas in discontinuing prolonged disease-modifying treatment for multiple sclerosis. Available at: 〈https://effectivehealthcare.ahrq.gov〉. (Accessed July 7).
2. Immunoablation and autologous haemopoietic stem cell transplantation for aggressive multiple sclerosis: a multicentre single group phase 2 trail;Atkins;Lancet,2016
3. Barkhof F., Cohen J.A., Coles A.J., 2015. Presented at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), October 7-10, Barcelona, Spain. Presentation 151.
4. Bowen J for the HALT-MS Investigators, 2016. Five year outcomes of HALT-MS: high-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for sever relapsing remitting multiple sclerosis. Presented at the 30th Annual Consortium of Multiple Sclerosis Centers (CMSC) Meeting, June 1-4, National Harbor, MD. Abstract DX05.
5. Coles A.J., Arnold D.L., Cohen J.A., et al., 2016. Patients with active RRMS and an inadequate response to prior therapy demonstrate durable improvements in relapse and disability following treatment with alemtuzumab: 5-year follow-up of the CARE-MS II study. Presented at Proceedings of the 68th Annual Meeting of the American Academy of Neurology, April 15-21, Vancouver, BC. Abstract P3.002.